Literature DB >> 30391133

Orphan nuclear receptor TR3/Nur77 differentially regulates the expression of integrins in angiogenesis.

Taiyang Ye1, Jin Peng2, Xin Liu3, Shiqiang Hou4, Gengming Niu5, Yan Li6, Huiyan Zeng7, Dezheng Zhao8.   

Abstract

Pathological angiogenesis is a hallmark of many diseases. Previously, we reported that orphan nuclear receptor TR3/Nur77 (human homolog, Nur77, mouse homolog) is a critical mediator of angiogenesis to regulate tumor growth and skin wound healing via down-regulating the expression of the junctional proteins and integrin β4. However, the molecular mechanism, by which TR3/Nur77 regulated angiogenesis, was still not completely understood. In this report by analyzing the integrin expression profile in endothelial cells, we found that the TR3/Nur77 expression highly increased the expression of integrins α1 and β5, decreased the expression of integrins α2 and β3, but had some or no effect on the expression of integrins αv, α3, α4, α5, α6, β1 and β7. In the angiogenic responses mediated by TR3/Nur77, integrin α1 regulated endothelial cell proliferation and adhesion, but not migration. Integrin β5 shRNA inhibited cell migration, but increased proliferation and adhesion. Integrin α2 regulated all of the endothelial cell proliferation, migration and adhesion. However, integrin β3 did not play any role in endothelial cell proliferation, migration and adhesion. TR3/Nur77 regulated the transcription of integrins α1, α2, β3 and β5, via various amino acid fragments within its transactivation domain and DNA binding domain. Furthermore, TR3/Nur77 regulated the integrin α1 promoter activity by directly interacting with a novel DNA element within the integrin α1 promoter. These studies furthered our understanding of the molecular mechanism by which TR3/Nur77 regulated angiogenesis, and supported our previous finding that TR3/Nur77 was an excellent therapeutic target for pathological angiogenesis. Therefore, targeting TR3/Nur77 inhibits several signaling pathways that are activated by various angiogenic factors.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Angiogenesis; Integrin; Migration; Proliferation; Promoter; TR3/Nur77

Mesh:

Substances:

Year:  2018        PMID: 30391133      PMCID: PMC6294663          DOI: 10.1016/j.mvr.2018.10.011

Source DB:  PubMed          Journal:  Microvasc Res        ISSN: 0026-2862            Impact factor:   3.514


  36 in total

Review 1.  Inflammation: a role for NR4A orphan nuclear receptors?

Authors:  Jason P McMorrow; Evelyn P Murphy
Journal:  Biochem Soc Trans       Date:  2011-04       Impact factor: 5.407

2.  Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates.

Authors:  Sonja Loges; Thomas Schmidt; Peter Carmeliet
Journal:  Genes Cancer       Date:  2010-01

3.  Activation of nerve growth factor-induced B alpha by methylene-substituted diindolylmethanes in bladder cancer cells induces apoptosis and inhibits tumor growth.

Authors:  Sung Dae Cho; Syng-Ook Lee; Sudhakar Chintharlapalli; Maen Abdelrahim; Shaheen Khan; Kyungsil Yoon; Ashish M Kamat; Stephen Safe
Journal:  Mol Pharmacol       Date:  2009-12-18       Impact factor: 4.436

4.  Evidence for Nr4a1 as a cold-induced effector of brown fat thermogenesis.

Authors:  Timo Kanzleiter; Tatjana Schneider; Isabel Walter; Florian Bolze; Christoph Eickhorst; Gerhard Heldmaier; Susanne Klaus; Martin Klingenspor
Journal:  Physiol Genomics       Date:  2005-10-11       Impact factor: 3.107

5.  DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo.

Authors:  Ji-Liang Li; Richard C A Sainson; Chern Ein Oon; Helen Turley; Russell Leek; Helen Sheldon; Esther Bridges; Wen Shi; Cameron Snell; Emma T Bowden; Herren Wu; Partha S Chowdhury; Angela J Russell; Craig P Montgomery; Richard Poulsom; Adrian L Harris
Journal:  Cancer Res       Date:  2011-07-29       Impact factor: 12.701

Review 6.  VEGF inhibition, hypertension, and renal toxicity.

Authors:  Suzanne R Hayman; Nelson Leung; Joseph P Grande; Vesna D Garovic
Journal:  Curr Oncol Rep       Date:  2012-08       Impact factor: 5.075

7.  Cytosporone B is an agonist for nuclear orphan receptor Nur77.

Authors:  Yanyan Zhan; Xiping Du; Hangzi Chen; Jingjing Liu; Bixing Zhao; Danhong Huang; Guideng Li; Qingyan Xu; Mingqing Zhang; Bart C Weimer; Dong Chen; Zhe Cheng; Lianru Zhang; Qinxi Li; Shaowei Li; Zhonghui Zheng; Siyang Song; Yaojian Huang; Zhiyun Ye; Wenjin Su; Sheng-Cai Lin; Yuemao Shen; Qiao Wu
Journal:  Nat Chem Biol       Date:  2008-09       Impact factor: 15.040

8.  The vascular permeabilizing factors histamine and serotonin induce angiogenesis through TR3/Nur77 and subsequently truncate it through thrombospondin-1.

Authors:  Liuliang Qin; Dezheng Zhao; Jianfeng Xu; Xianghui Ren; Ernest F Terwilliger; Sareh Parangi; Jack Lawler; Harold F Dvorak; Huiyan Zeng
Journal:  Blood       Date:  2013-01-11       Impact factor: 22.113

9.  Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells.

Authors:  Farbod Shojaei; Xiumin Wu; Ajay K Malik; Cuiling Zhong; Megan E Baldwin; Stefanie Schanz; Germaine Fuh; Hans-Peter Gerber; Napoleone Ferrara
Journal:  Nat Biotechnol       Date:  2007-07-29       Impact factor: 54.908

10.  NR4A1 (Nur77) mediates thyrotropin-releasing hormone-induced stimulation of transcription of the thyrotropin β gene: analysis of TRH knockout mice.

Authors:  Yasuyo Nakajima; Masanobu Yamada; Ryo Taguchi; Nobuyuki Shibusawa; Atsushi Ozawa; Takuya Tomaru; Koshi Hashimoto; Tsugumichi Saito; Takafumi Tsuchiya; Shuichi Okada; Tetsurou Satoh; Masatomo Mori
Journal:  PLoS One       Date:  2012-07-09       Impact factor: 3.240

View more
  6 in total

1.  DLL4 and Jagged1 are angiogenic targets of orphan nuclear receptor TR3/Nur77.

Authors:  Jin Peng; Shengqiang Zhao; Yan Li; Gengming Niu; Chen Chen; Taiyang Ye; Dezheng Zhao; Huiyan Zeng
Journal:  Microvasc Res       Date:  2019-03-28       Impact factor: 3.514

2.  Hypoxia-induced Nur77 activates PI3K/Akt signaling via suppression of Dicer/let-7i-5p to induce epithelial-to-mesenchymal transition.

Authors:  Zeyu Shi; Sally K Y To; Shuaishuai Zhang; Shan Deng; Margarita Artemenko; Minda Zhang; Juan Tang; Jin-Zhang Zeng; Alice S T Wong
Journal:  Theranostics       Date:  2021-01-19       Impact factor: 11.556

Review 3.  Targeting NR4A Nuclear Receptors to Control Stromal Cell Inflammation, Metabolism, Angiogenesis, and Tumorigenesis.

Authors:  Daniel Crean; Evelyn P Murphy
Journal:  Front Cell Dev Biol       Date:  2021-02-09

Review 4.  Therapeutic potential of NR4A1 in cancer: Focus on metabolism.

Authors:  Shan Deng; Bo Chen; Jiege Huo; Xin Liu
Journal:  Front Oncol       Date:  2022-08-16       Impact factor: 5.738

Review 5.  NR4A1-3 nuclear receptor activity and immune cell dysregulation in rheumatic diseases.

Authors:  Evelyn P Murphy; Daniel Crean
Journal:  Front Med (Lausanne)       Date:  2022-07-22

6.  TRM integrins CD103 and CD49a differentially support adherence and motility after resolution of influenza virus infection.

Authors:  Emma C Reilly; Kris Lambert Emo; Patrick M Buckley; Nicholas S Reilly; Ian Smith; Francisco A Chaves; Hongmei Yang; Patrick W Oakes; David J Topham
Journal:  Proc Natl Acad Sci U S A       Date:  2020-05-21       Impact factor: 12.779

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.